vs
Mechanics Bancorp（MCHB）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Mechanics Bancorp的1.7倍（$772.1M vs $458.8M），Mechanics Bancorp自由现金流更多（$187.1M vs $161.8M），过去两年Mechanics Bancorp的营收复合增速更高（232.1% vs 9.0%）
Mechanics Bancorp是总部位于美国的银行控股公司，核心子公司为Mechanics Bank，提供零售银行、商业银行及财富管理类服务，覆盖储蓄账户、各类贷款、投资咨询等业务，主要服务加利福尼亚州的个人消费者及中小型企业客户。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MCHB vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.7倍
$458.8M
自由现金流更多
MCHB
多$25.3M
$161.8M
两年增速更快
MCHB
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $458.8M | $772.1M |
| 净利润 | — | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | — | 12.7% |
| 营收同比 | — | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MCHBRVTY
| Q4 25 | $458.8M | $772.1M | ||
| Q3 25 | $255.4M | $698.9M | ||
| Q2 25 | $49.0M | $720.3M | ||
| Q1 25 | $45.4M | $664.8M | ||
| Q4 24 | $29.6M | $729.4M | ||
| Q3 24 | $147.9M | $684.0M | ||
| Q2 24 | $42.9M | $691.7M | ||
| Q1 24 | $41.6M | $649.9M |
净利润MCHBRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $55.2M | $46.7M | ||
| Q2 25 | $-4.4M | $53.9M | ||
| Q1 25 | $-4.5M | $42.2M | ||
| Q4 24 | $-123.3M | $94.6M | ||
| Q3 24 | $39.9M | $94.4M | ||
| Q2 24 | $-6.2M | $55.4M | ||
| Q1 24 | $-7.5M | $26.0M |
毛利率MCHBRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率MCHBRVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | 17.7% | 11.7% | ||
| Q2 25 | -9.8% | 12.6% | ||
| Q1 25 | -10.5% | 10.9% | ||
| Q4 24 | -312.2% | 16.3% | ||
| Q3 24 | 37.5% | 14.3% | ||
| Q2 24 | -18.6% | 12.4% | ||
| Q1 24 | -25.4% | 6.8% |
净利率MCHBRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | 21.6% | 6.7% | ||
| Q2 25 | -9.0% | 7.5% | ||
| Q1 25 | -9.8% | 6.4% | ||
| Q4 24 | -416.4% | 13.0% | ||
| Q3 24 | 27.0% | 13.8% | ||
| Q2 24 | -14.5% | 8.0% | ||
| Q1 24 | -18.0% | 4.0% |
每股收益（稀释后）MCHBRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | $0.26 | $0.40 | ||
| Q2 25 | $-0.23 | $0.46 | ||
| Q1 25 | $-0.24 | $0.35 | ||
| Q4 24 | $-6.53 | $0.77 | ||
| Q3 24 | $0.20 | $0.77 | ||
| Q2 24 | $-0.33 | $0.45 | ||
| Q1 24 | $-0.40 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.0B | $919.9M |
| 总债务越低越好 | $192.0M | — |
| 股东权益账面价值 | $2.9B | $7.3B |
| 总资产 | $22.4B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资MCHBRVTY
| Q4 25 | $1.0B | $919.9M | ||
| Q3 25 | $1.4B | $931.4M | ||
| Q2 25 | $201.1M | $991.8M | ||
| Q1 25 | $252.2M | $1.1B | ||
| Q4 24 | $999.7M | $1.2B | ||
| Q3 24 | $205.9M | $1.2B | ||
| Q2 24 | $218.7M | $2.0B | ||
| Q1 24 | $320.3M | $1.7B |
总债务MCHBRVTY
| Q4 25 | $192.0M | — | ||
| Q3 25 | $190.1M | — | ||
| Q2 25 | $225.3M | — | ||
| Q1 25 | $225.2M | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $224.9M | — | ||
| Q1 24 | $224.9M | — |
股东权益MCHBRVTY
| Q4 25 | $2.9B | $7.3B | ||
| Q3 25 | $2.8B | $7.4B | ||
| Q2 25 | $2.4B | $7.6B | ||
| Q1 25 | $400.8M | $7.6B | ||
| Q4 24 | $2.3B | $7.7B | ||
| Q3 24 | $2.3B | $7.9B | ||
| Q2 24 | $2.2B | $7.9B | ||
| Q1 24 | $527.3M | $7.8B |
总资产MCHBRVTY
| Q4 25 | $22.4B | $12.2B | ||
| Q3 25 | $22.7B | $12.1B | ||
| Q2 25 | $7.6B | $12.4B | ||
| Q1 25 | $7.8B | $12.4B | ||
| Q4 24 | $16.5B | $12.4B | ||
| Q3 24 | $9.2B | $12.8B | ||
| Q2 24 | $9.3B | $13.4B | ||
| Q1 24 | $9.5B | $13.4B |
负债/权益比MCHBRVTY
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.07× | — | ||
| Q2 25 | 0.09× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.10× | — | ||
| Q1 24 | 0.43× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $193.6M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $187.1M | $161.8M |
| 自由现金流率自由现金流/营收 | 40.8% | 21.0% |
| 资本支出强度资本支出/营收 | 1.4% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $263.7M | $509.4M |
8季度趋势，按日历期对齐
经营现金流MCHBRVTY
| Q4 25 | $193.6M | $182.0M | ||
| Q3 25 | $112.0M | $138.5M | ||
| Q2 25 | $-9.8M | $134.3M | ||
| Q1 25 | $-22.5M | $128.2M | ||
| Q4 24 | $292.3M | $174.2M | ||
| Q3 24 | $247.0M | $147.9M | ||
| Q2 24 | $-21.8M | $158.6M | ||
| Q1 24 | $-7.8M | $147.6M |
自由现金流MCHBRVTY
| Q4 25 | $187.1M | $161.8M | ||
| Q3 25 | $109.1M | $120.0M | ||
| Q2 25 | $-9.9M | $115.5M | ||
| Q1 25 | $-22.6M | $112.2M | ||
| Q4 24 | $285.9M | $149.8M | ||
| Q3 24 | $244.5M | $125.6M | ||
| Q2 24 | $-22.0M | $136.6M | ||
| Q1 24 | $-13.9M | $129.7M |
自由现金流率MCHBRVTY
| Q4 25 | 40.8% | 21.0% | ||
| Q3 25 | 42.7% | 17.2% | ||
| Q2 25 | -20.2% | 16.0% | ||
| Q1 25 | -49.7% | 16.9% | ||
| Q4 24 | 965.3% | 20.5% | ||
| Q3 24 | 165.4% | 18.4% | ||
| Q2 24 | -51.3% | 19.7% | ||
| Q1 24 | -33.4% | 20.0% |
资本支出强度MCHBRVTY
| Q4 25 | 1.4% | 2.6% | ||
| Q3 25 | 1.1% | 2.6% | ||
| Q2 25 | 0.2% | 2.6% | ||
| Q1 25 | 0.1% | 2.4% | ||
| Q4 24 | 21.5% | 3.4% | ||
| Q3 24 | 1.7% | 3.3% | ||
| Q2 24 | 0.7% | 3.2% | ||
| Q1 24 | 14.6% | 2.7% |
现金转化率MCHBRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 2.03× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 6.18× | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MCHB
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
